Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

By R. Motzer, Thomas E. Hutson, P. Tomczak, M. Michaelson, R. Bukowski, S. Oudard, S. Négrier, C. Szczylik, R. Pili, G. Bjarnason and 9 more. Journal of Clinical Oncology, 2009

2,196 citations recorded by the source corpus.

Subfields: Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/e43345f4ce8ef2ceb4bef80df5d990afa4a14046

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. W. Marston Linehan
2. Laura S. Schmidt
3. R. Srinivasan
4. B. Rini

In Pulmonary and Respiratory Medicine

1. B. Rini

Citations in the corpus

• EAU guidelines on renal cell carcinoma: the 2010 update. (2010, background): “In a phase 3 first-line trial comparing sunitinib with IFN-a, sunitinib achieved a longer progression-free survival than IFN-a (11 vs 5 mo), although this benefit was restricted to low- and intermediate-risk patients [44].”
• Systemic therapy in metastatic renal cell carcinoma (2016, background): “051), probably due to the survival endpoint being confounded by crossover to sunitinib [17].”
• EAU guidelines on renal cell carcinoma: 2014 update. (2010, neutral): “In a phase 3 first-line trial comparing sunitinib with IFN-a, sunitinib achieved a longer progression-free survival than IFN-a (11 vs 5 mo), although this benefit was restricted to low- and intermediate-risk patients [44].”
• A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “6 mth NS Improved 4 [124][125]”
• Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. (2010, background): “The fact that other contemporary phase III trials, including trials investigating sunitinib and sorafenib and the other phase III investigation of IFN- plus bevacizumab versus IFN- , have also failed to demonstrate a statistically significant OS advantage suggests that the same confounding effect of”
• Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions (2014, neutral): “1 months) [12].”
• The genetic basis of kidney cancer: a metabolic disease (2010, background): “However, even the most commonly used agent, sunitinib, has a partial response rate of only 31% and a progression free advantage over interferon of 6 months (11 versus 5 months).(82) Most patients with advanced kidney cancer treated with targeted agents eventually progress and there are very few long”